| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,334,110 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Mosseri Marlio Charles | 10 percent owner | 1 | $916,000 | 0 | $0 | $916,000 |
| BENTSUR RON | Chairman & CEO | 2 | $278,600 | 0 | $0 | $278,600 |
| Sanchez Juan | director | 1 | $75,270 | 0 | $0 | $75,270 |
| Kaplan Matthew L. | director | 1 | $64,240 | 0 | $0 | $64,240 |
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Over the last 12 months, insiders at Nuvectis Pharma, Inc. have bought $1.33M and sold $0 worth of Nuvectis Pharma, Inc. stock.
On average, over the past 5 years, insiders at Nuvectis Pharma, Inc. have bought $2.41M and sold $22,478 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mosseri Marlio Charles (10 percent owner) — $916,000. BENTSUR RON (Chairman & CEO) — $278,600. Sanchez Juan (director) — $75,270.
The last purchase of 12,500 shares for transaction amount of $250,000 was made by BENTSUR RON (Chairman & CEO) on 2026‑06‑30.
| 2026-06-30 | BENTSUR RON | Chairman & CEO | 12,500 0.0513% | $20.00 | $250,000 | +9.52% | ||
| 2026-06-30 | Mosseri Marlio Charles | 10 percent owner | 50,000 0.1878% | $18.32 | $916,000 | +9.52% | ||
| 2025-11-05 | BENTSUR RON | Chairman & CEO | 5,000 0.0167% | $5.72 | $28,600 | +68.85% | ||
| 2025-11-05 | Kaplan Matthew L. | director | 11,000 0.0376% | $5.84 | $64,240 | +68.85% | ||
| 2025-11-05 | Sanchez Juan | director | 13,000 0.0441% | $5.79 | $75,270 | +68.85% | ||
| 2025-10-27 | Mosseri Marlio Charles | 10 percent owner | 72,836 0.299% | $6.28 | $457,410 | +38.02% | ||
| 2025-10-24 | Mosseri Marlio Charles | 10 percent owner | 35,034 0.1408% | $6.15 | $215,459 | +45.81% | ||
| 2025-10-23 | Mosseri Marlio Charles | 10 percent owner | 46,900 0.1858% | $6.06 | $284,214 | +50.42% | ||
| 2025-06-20 | Mosseri Marlio Charles | 10 percent owner | 5,603 0.0264% | $7.99 | $44,768 | -4.00% | ||
| 2025-06-18 | Mosseri Marlio Charles | 10 percent owner | 28,043 0.1342% | $8.05 | $225,746 | -2.98% | ||
| 2025-06-17 | Mosseri Marlio Charles | 10 percent owner | 5,399 0.0258% | $8.11 | $43,786 | -3.70% | ||
| 2025-05-12 | Mosseri Marlio Charles | 10 percent owner | 21,167 0.0866% | $8.11 | $171,664 | -6.91% | ||
| 2025-05-09 | Mosseri Marlio Charles | 10 percent owner | 25,062 0.1054% | $8.94 | $223,965 | -13.18% | ||
| 2025-05-08 | Mosseri Marlio Charles | 10 percent owner | 2,600 0.0107% | $8.96 | $23,298 | -15.29% | ||
| 2025-05-07 | Mosseri Marlio Charles | 10 percent owner | 12,317 0.0516% | $8.59 | $105,770 | -10.84% | ||
| 2025-05-06 | Mosseri Marlio Charles | 10 percent owner | 12,444 0.051% | $8.59 | $106,955 | -12.83% | ||
| 2025-02-07 | Mosseri Marlio Charles | 10 percent owner | 240,000 0.8579% | $5.00 | $1.2M | +13.79% | ||
| 2024-12-24 | BENTSUR RON | Chairman & CEO | 4,500 0.0233% | $4.65 | $20,925 | +48.71% | ||
| 2024-12-13 | Mosseri Marlio Charles | 10 percent owner | 17,000 0.0872% | $4.70 | $79,900 | +44.68% | ||
| 2024-12-12 | Mosseri Marlio Charles | 10 percent owner | 32,121 0.1662% | $4.64 | $149,041 | +46.23% |
| BENTSUR RON | Chairman & CEO | 3688424 11.2989% | $71.33M | 57 | 0 | <0.0001% |
| Mosseri Marlio Charles | 10 percent owner | 3186576 9.7616% | $61.63M | 34 | 0 | <0.0001% |
| Kaplan Matthew L. | director | 124760 0.3822% | $2.41M | 2 | 0 | <0.0001% |
| Sanchez Juan | director | 78150 0.2394% | $1.51M | 1 | 0 | |
| Poradosu Enrique | Chief Science & Business Off | 1506319 4.6144% | $29.13M | 6 | 0 | +27.24% |
| Shemesh Shay | Chief Dev. & Ops. Officer | 1493068 4.5738% | $28.88M | 13 | 0 | +28.02% |
| Hoberman Kenneth | 55140 0.1689% | $1.07M | 1 | 0 | <0.0001% |
Nuvectis Pharma, Inc. (NVCT) | $10,154,205 | 103 | -4.60% | $631.34M |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M |
| Increased Positions | 29 | +67.44% | 751,886 | +20.35% |
| Decreased Positions | 16 | -37.21% | 207,996 | -5.63% |
| New Positions | 3 | New | 17,874 | New |
| Sold Out Positions | 8 | Sold Out | 136,636 | Sold Out |
| Total Postitions | 56 | +30.23% | 4M | +14.72% |
| Vanguard Group Inc | $5,946.00 | 2.69% | 698,708 | +31,903 | +4.78% | 2025-09-30 |
| Blackrock, Inc. | $5,832.00 | 2.64% | 685,337 | +42,355 | +6.59% | 2025-09-30 |
| Iridian Asset Management Llc/Ct | $3,452.00 | 1.56% | 405,621 | +32,904 | +8.83% | 2025-09-30 |
| Baldwin Wealth Partners Llc/Ma | $2,982.00 | 1.35% | 350,461 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $2,772.00 | 1.25% | 325,733 | +40,401 | +14.16% | 2025-09-30 |
| Occam Crest Management Lp | $2,468.00 | 1.12% | 290,000 | +290,000 | New | 2025-09-30 |
| State Street Corp | $1,163.00 | 0.53% | 136,716 | +23,137 | +20.37% | 2025-09-30 |
| Northern Trust Corp | $908.00 | 0.41% | 106,641 | -3,176 | -2.89% | 2025-09-30 |
| Susquehanna International Group, Llp | $773.00 | 0.35% | 90,879 | +45,605 | +100.73% | 2025-09-30 |
| Oppenheimer & Co Inc | $588.00 | 0.27% | 69,066 | 0 | 0% | 2025-09-30 |